Latest Peptide News
Peptide News — page 3
Retatrutide Cardiovascular Outcomes Trial Reaches Full Enrollment
The registry entry for TRIUMPH-Outcomes, the phase 3 retatrutide cardiovascular outcomes trial, was updated on August 24 to show the study active and closed to new participants. It is the largest single trial in Eli Lilly's retatrutide program and the one that will decide whether the triple agonist can claim organ-protection benefits rather than weight loss alone.
GLP-1 Non-Responders: New Review Asks If Response Can Be Predicted
A review indexed this month in Diabetes, Obesity & Metabolism takes on one of the least discussed features of incretin therapy: the substantial minority of people who get far less from it than trial averages suggest. Alongside new subgroup work on tirzepatide in women with polycystic ovary syndrome and a paper on muscle mass during incretin-based weight loss, the question of what separates GLP-1 non-responders from responders is moving from anecdote to research agenda.
Semaglutide cognitive side effects: 13,007-patient BMJ study
Three peer-reviewed papers examining semaglutide cognitive side effects and broader neuropsychiatric signals from GLP-1 receptor agonists were indexed within days of each other. The largest is a retrospective cohort of 13,007 people in the United States who already carried a psychiatric diagnosis.
Retatrutide Phase 3 Trial Completed in 2,335-Person Obesity Study
A ClinicalTrials.gov record updated August 21, 2026 shows Eli Lilly's largest registered retatrutide phase 3 trial completed after enrolling 2,335 participants with obesity or overweight. No outcome data has been posted to the registry yet, and retatrutide remains an investigational drug with no marketing approval anywhere.
Once-Monthly Semaglutide Depot Begins Phase 1/2a Human Trial
A registry entry posted this week describes a Phase 1/2a study of a once-monthly semaglutide depot in adults with type 2 diabetes. If the formulation holds up in later trials, it would change the interval that millions of people currently build their GLP-1 protocols around.
Oral Semaglutide Weight Loss Trial Opens With Lower-Dose Focus
A new Phase 3 oral semaglutide weight loss trial appeared on ClinicalTrials.gov this week with 450 planned participants and a stated goal of identifying a lower tablet dose. Two other oral semaglutide studies — one in East Asian adults with obesity, one testing a reformulated tablet in Japan — are now listed as completed.
Retatrutide Cardiovascular Risk Biomarkers Improve in New Analysis
Researchers reporting in Diabetes, Obesity & Metabolism describe improvements in retatrutide cardiovascular risk biomarkers in adults with obesity, with and without type 2 diabetes. It is the kind of result that shapes expectations for a drug still years from any approval — and it is not the same thing as an outcomes trial.
GLP-1 Gastroparesis Reviewed as Aspiration Questions Persist
Two new publications tackle the same underlying problem from different ends: a PLOS One systematic review of GLP-1 gastroparesis cases, and an Anaesthesia letter on gastric contents and aspiration risk after semaglutide cessation. Both matter to anyone on an incretin drug who has a procedure coming up.
Compounded Tirzepatide Facial Nodules Case Report Draws a Rebuttal
A dermatology case report attributing compounded tirzepatide facial nodules to inflammation has drawn a published rebuttal arguing that infection and biofilm were never ruled out. The exchange is a useful window into how thin the evidence still is when a compounded GLP-1 product and a cosmetic filler are in the same patient.
Tirzepatide Combination Therapy Trials: Four New Add-On Studies
Registry records posted in the second week of August 2026 show a cluster of tirzepatide combination therapy trials and semaglutide add-on studies, where the approved drug is the floor and the experimental agent has to prove it adds something. One Roche study even withdraws tirzepatide partway through to see what holds.
Semaglutide Alcohol Use Disorder Trial Enrolls 622 Veterans
The largest test yet of a GLP-1 receptor agonist for drinking has opened enrollment: a VA-sponsored semaglutide alcohol use disorder trial seeking 622 participants. It follows a smaller federally funded phase 2 study and observational reports on smoking and mood in another patient population.
Retatrutide Grey Market Tested: Australian Study Checks Labels
A research letter in Drug and Alcohol Review reports laboratory analysis of vials sold under the retatrutide name in Australia — a direct look at what circulates in the retatrutide grey market. It lands while the compound itself is still years from any approval decision, with a 4,500-participant liver outcomes trial now recruiting.